Breaking News, Collaborations & Alliances

Algen and AstraZeneca Forge AI-Driven Drug Discovery Partnership

Aim to drive the discovery of novel cell-type specific disease targets using the AIgenBrain functional genomics platform.

Author Image

By: Charlie Sternberg

Associate Editor

Algen Biotechnologies has entered into a multi-target research collaboration with AstraZeneca to accelerate the identification of novel therapeutic targets in immunology. The partnership will leverage Algen’s proprietary AlgenBrain platform, which integrates CRISPR-based gene modulation with artificial intelligence to model disease progression and uncover actionable biological insights. Under the agreement, Algen will apply its platform to drive preclinical drug discovery, while AstraZeneca w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters